Juillerat Pascal, Christen-Zäch Stephanie, Troillet François-Xavier, Gallot-Lavallée Suzanne, Pannizzon Renato G, Michetti Pierre
Division of Gastroenterology and Hepatology, University of Lausanne, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Dermatology. 2007;215(3):245-51. doi: 10.1159/000106584.
We report the case of a 19-year-old woman who developed an acute disseminated pyoderma gangrenosum (PG) during a severe flare of ulcerative colitis (UC). She was successfully treated with a 3-dose regimen of the anti-tumor-necrosis-factor-alpha antibody infliximab. The literature on the effectiveness of this biological agent was reviewed, including 8 other cases of UC-associated PG and 77 cases of Crohn's-disease-associated PG. This case report and the review of the literature demonstrate that infliximab can be successfully used to treat patients with PG associated with inflammatory bowel diseases.
我们报告了一名19岁女性的病例，该患者在溃疡性结肠炎（UC）严重发作期间发生了急性播散性坏疽性脓皮病（PG）。她接受了3剂抗肿瘤坏死因子-α抗体英夫利昔单抗治疗，治疗成功。我们回顾了关于这种生物制剂有效性的文献，包括另外8例UC相关PG病例和77例克罗恩病相关PG病例。本病例报告及文献回顾表明，英夫利昔单抗可成功用于治疗与炎症性肠病相关的PG患者。
